JNJ's Subcutaneous Regimen Shows Promise in Advanced EGFR-Mutated NSCLC
Johnson & Johnson (JNJ) has released new data from its COPERNICUS Phase 2b trial, showing that its subcutaneous regimen of RYBREVANT FASPRO plus LAZCLUZE in advanced EGFR-mutated non-small cell lung cancer (NSCLC) results in lower side effects compared to existing treatments.
The study found reduced treatment-related adverse events, including fewer instances of rash, administration reactions, and venous thromboembolism (VTE), when compared to the MARIPOSA IV regimen. This is significant because it suggests that the subcutaneous combination can be administered more frequently, potentially improving patient outcomes.
The data also aligns with Johnson & Johnson's broader research and development efforts in oncology, which are focused on refining existing medicines rather than launching new ones. While policy risk and litigation remain concerns for the company, this news provides a promising update on its pharmaceutical pipeline.